Revenio Group Oyj - Total number of voting rights and capital

Revenio Group Corporation: Increased number of shares entered into trade register

Revenio Group Corporation, Stock Exchange Release, June 4, 2015 at 09:00

Increased number of shares entered into trade register

2,211 new share subscriptions based on the company's 2007C stock options
approved by the Board of Directors of Revenio Group Corporation on May
21, 2015, have been entered into the trade register today. The share
subscription price under 2007C option rights was 1.24 EUR per share. The
subscription period for 2007C options is to June 1, 2016.

After these subscriptions, the number of Revenio Group Corporation's shares and
votes will rise to 7,935,289. These increases were recorded in their entirety in
the unrestricted shareholders' equity fund.

Revenio Group Corporation has applied for the listing of its new shares on the
Nasdaq Helsinki in the same series as the company's existing shares. According
to the current estimate, the new shares will be listed on June 5, 2015.

Revenio Group Oyj
Olli-Pekka Salovaara
CEO


For further information, please contact:

President & CEO Olli-Pekka Salovaara, tel. +358 40 567 5520
olli-pekka.salovaara@revenio.fi
www.revenio.fi

DISTRIBUTION:
NASDAQ Helsinki
Financial Supervisory Authority (FIN-FSA)
Principal media
www.revenio.fi


The Revenio Group in brief

Revenio is a Finnish health tech group whose core business is in tonometers. The
Revenio Health Tech segment comprises the business operations of Icare Finland
Oy, Revenio Research Oy and Oscare Medical Oy, which specializes in osteoporosis
screening and monitoring. The common denominators of Revenio's business
operations include screening, follow-up and the global need to make cost savings
in health care via preventive measures. Revenio seeks vigorous growth in health
technology, both organically and through acquisitions and mergers. Revenio aims
at developing even more efficient and easily adopted methods for the early-stage
detection of diseases with significance for public health. The focus of
Revenio's screening technology lies on the early detection of glaucoma,
osteoporosis, skin cancer and asthma, and the monitoring of these during the
treatment process.

In 2014, the Revenio Group's net sales totaled MEUR 16.0, with its operating
profit (EBIT) from continuing operations standing at 27.5%. The Revenio Group
Corporation is listed on NASDAQ OMX Helsinki.


[HUG#1926236]